A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

(2012) A. J. Jakubowiak et al.   BLOOD

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma

(2012) M. Alsina et al.   CLINICAL CANCER RESEARCH

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

(2012) B. Arnulf et al.   HAEMATOLOGICA

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events

(2011) S. Arastu-Kapur et al.   CLINICAL CANCER RESEARCH

Future Directions of Next-Generation Novel Therapies, Combination Approaches, and the Development of Personalized Medicine in Myeloma

(2011) Constantine S. Mitsiades et al.   JOURNAL OF CLINICAL ONCOLOGY

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents

(2011) B Mohty et al.   LEUKEMIA

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Treatment of relapsed and refractory multiple myeloma in the era of novel agents

(2010) Niels W.C.J. van de Donk et al.   CANCER TREATMENT REVIEWS

Proteasome inhibitors increase tubulin polymerization and stabilization in tissue culture cells: A possible mechanism contributing to peripheral neuropathy and cellular toxicity following proteasome inhibition

(2010) Marianne S. Poruchynsky et al.   CELL CYCLE

Outcome and Toxicity in the Modern Era of New Drugs for Multiple Myeloma: A Reappraisal for Comparison With Future Investigational Trials

(2010) Massimo Offidani et al.   Clinical Lymphoma Myeloma & Leukemia

Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice

(2010) Jordi Bruna et al.   EXPERIMENTAL NEUROLOGY

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations

(2010) B. Mohty et al.   HAEMATOLOGICA

Advances in treatment for relapses and refractory multiple myeloma

(2010) Tiffany Richards et al.   MEDICAL ONCOLOGY

Management of disease- and treatment-related complications in patients with multiple myeloma

(2010) Francesca Gay et al.   MEDICAL ONCOLOGY

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

(2009) Paul G. Richardson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates

(2009) Brenda K. Edwards et al.   CANCER

The nuclear signaling of NF-κB: current knowledge, new insights and future perspectives

(2009) Fengyi Wan et al.   CELL RESEARCH

A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies

(2009) O. A. O'Connor et al.   CLINICAL CANCER RESEARCH

The proteasomal system

(2009) Tobias Jung et al.   MOLECULAR ASPECTS OF MEDICINE

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

(2008) R A Kyle et al.   LEUKEMIA